VRG 50635
Alternative Names: VRG-50635Latest Information Update: 27 Mar 2024
At a glance
- Originator Verge Genomics
- Class Small molecules
- Mechanism of Action PIKFYVE protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
Most Recent Events
- 25 Mar 2024 Verge Genomics and Ferrer agree to co-develop and commercialize VRG 50635 in in Europe, Central and South America, Southeast Asia and Japan for Amyotrophic lateral sclerosis
- 29 Feb 2024 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in USA (PO) (NCT06286475)
- 28 Feb 2024 Verge Genomics plans phase-I safety and pharmacokinetics trial (In volunteers) in USA (NCT06286475)